Correspondingly, we observed that combined inhibition of Pak1 and CaMKII has a potent synergistic effect in Her2 positive and TNBC cells in vitro, and may represent an attractive therapeutic target for the treatment of breast cancer. Here, PAK1 is linked to breast carcinoma.